A pharmaceutical portfolio review should end with a manageable decision list. Divide the catalogue into presentations to investigate now, presentations to defer and entries that need more product information before they can be assessed.
Define your inclusion criteria first
Write down the buyer channels, intended market and product requirements relevant to the review. Decide which facts must be present before a line can move forward. This prevents a large catalogue from becoming a list of everything that might be interesting.
Use a coverage matrix
| Presentation | Buyer requirement | Information gap | Next decision |
|---|---|---|---|
| Exact name and URL | The documented need it may address | The fact or evidence still required | Investigate, defer or clarify |
Record strengths and saleable packs separately. Two artwork records should not automatically count as two distinct products. Equally, do not merge records merely because their ingredient names match.
Review the shortlist across teams
Commercial interest is one part of the assessment. The people responsible for product review, local requirements and operations may identify questions that change the scope. Give them the actual presentation references instead of only a category total.
Use the Dr. ICO catalogue to identify candidates, then request current information for those candidates. Catalogue inclusion alone does not establish supply terms or the status of a product in the proposed destination.
Keep the outcome proportionate
Document why each retained product deserves the next enquiry. A concise shortlist with traceable reasoning is easier to discuss than an unranked catalogue export. Revisit deferred lines when the evidence or requirement changes, retaining the date and reason for that revision.
